Jincheng Pharmaceuticals: Subsidiary Receives CEP Certificate for Chemical Active Pharmaceutical Ingredients

Jincheng Pharmaceuticals announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., recently received the European Pharmacopoeia certificate of suitability for the active pharmaceutical ingredient Oseltamivir Phosphate issued by the European Medicines Agency. The certificate is valid from July 25, 2025, with the number CEP 2023-418. Oseltamivir Phosphate is a selective neuraminidase inhibitor of influenza virus, mainly used clinically for the treatment of influenza A and B in adults, children aged 1 year and older, and for the prevention of influenza A and B in adults and adolescents aged 13 years and older. In 2024, global sales of the drug reached $1.017 billion with a raw material consumption of 92.31 metric tons. This CEP certificate will help Jincheng Tail further expand its overseas market and enhance its competitiveness in the raw material market.